Real-world impact of integrating HIV assisted partner services into 31 facilities in Kenya: a single-arm, hybrid type 2 implementation-effectiveness study.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
16
07
2022
revised:
14
02
2023
accepted:
27
02
2023
medline:
18
4
2023
entrez:
15
4
2023
pubmed:
16
4
2023
Statut:
ppublish
Résumé
Assisted partner services (APS), or exposure notification and HIV testing for sexual partners of individuals diagnosed with HIV (index clients), have been shown to be safe and effective in clinical trials. We assessed the real-world effectiveness of APS when integrated into HIV clinics in western Kenya. In this single-arm, hybrid type 2 implementation science study, we facilitated APS implementation in 31 health facilities in Kenya by training existing health-care staff. We focused on male partner outcomes to assess the impact of APS in reaching male individuals in sub-Saharan Africa, who have lower rates of HIV testing than female individuals. Female individuals (aged ≥18 years or emancipated minor) who tested positive for HIV at participating facilities in Kenya were offered APS; consenting female participants provided contact information for all male sexual partners in the past 3 years. Male partners were notified of their potential HIV exposure and offered a choice of community-based or facility-based HIV testing services (HTS). Female index clients and male partners with HIV were followed up at 6 weeks, 6 months, and 12 months after enrolment, to assess linkage to antiretroviral treatment. Viral load was assessed at 12 months. Between May 1, 2018, and March 31, 2020, 32 722 female individuals received HTS; 1910 (6%) tested positive for HIV, of whom 1724 (90%) received APS. Female index clients named 5137 male partners (median 3 per index [IQR 2-4]), of whom 4422 (86%) were reached with exposure notification and HTS. 524 (12%) of the male partners tested were newly diagnosed with HIV and 1292 (29%) reported a previous HIV diagnosis. At 12 months follow-up, 1512 (88%) female index clients and 1621 (89%) male partners with HIV were taking ART, with few adverse events: 25 (2%) female index clients and seven (<1%) male partners reported intimate partner violence, and 60 (3%) female index clients and ten (<1%) male partners reported relationship dissolution. Evidence from this real-world APS scale-up project shows that APS is a safe, acceptable, and effective strategy to identify males with HIV and retain them in care. The US National Institutes of Health.
Sections du résumé
BACKGROUND
Assisted partner services (APS), or exposure notification and HIV testing for sexual partners of individuals diagnosed with HIV (index clients), have been shown to be safe and effective in clinical trials. We assessed the real-world effectiveness of APS when integrated into HIV clinics in western Kenya.
METHODS
In this single-arm, hybrid type 2 implementation science study, we facilitated APS implementation in 31 health facilities in Kenya by training existing health-care staff. We focused on male partner outcomes to assess the impact of APS in reaching male individuals in sub-Saharan Africa, who have lower rates of HIV testing than female individuals. Female individuals (aged ≥18 years or emancipated minor) who tested positive for HIV at participating facilities in Kenya were offered APS; consenting female participants provided contact information for all male sexual partners in the past 3 years. Male partners were notified of their potential HIV exposure and offered a choice of community-based or facility-based HIV testing services (HTS). Female index clients and male partners with HIV were followed up at 6 weeks, 6 months, and 12 months after enrolment, to assess linkage to antiretroviral treatment. Viral load was assessed at 12 months.
FINDINGS
Between May 1, 2018, and March 31, 2020, 32 722 female individuals received HTS; 1910 (6%) tested positive for HIV, of whom 1724 (90%) received APS. Female index clients named 5137 male partners (median 3 per index [IQR 2-4]), of whom 4422 (86%) were reached with exposure notification and HTS. 524 (12%) of the male partners tested were newly diagnosed with HIV and 1292 (29%) reported a previous HIV diagnosis. At 12 months follow-up, 1512 (88%) female index clients and 1621 (89%) male partners with HIV were taking ART, with few adverse events: 25 (2%) female index clients and seven (<1%) male partners reported intimate partner violence, and 60 (3%) female index clients and ten (<1%) male partners reported relationship dissolution.
INTERPRETATION
Evidence from this real-world APS scale-up project shows that APS is a safe, acceptable, and effective strategy to identify males with HIV and retain them in care.
FUNDING
The US National Institutes of Health.
Identifiants
pubmed: 37061312
pii: S2214-109X(23)00153-5
doi: 10.1016/S2214-109X(23)00153-5
pmc: PMC10156000
mid: NIHMS1892579
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e749-e758Subventions
Organisme : NIAID NIH HHS
ID : R01 AI134130
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH115789
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009580
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009783
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010905
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests CF, MS, BJW, and DK report grants from the National Institutes of Health, outside of the submitted work. MS reports grants from the Bill & Melinda Gates Foundation, outside of the submitted work. All other authors declare no competing interests.
Références
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25310
pubmed: 31321902
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25308
pubmed: 31321882
J Int AIDS Soc. 2019 Oct;22(10):e25398
pubmed: 31631576
AIDS. 2019 Feb 1;33(2):349-352
pubmed: 30557162
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
Trop Med Int Health. 2011 Jul;16(7):828-9
pubmed: 21418449
AIDS. 2017 Aug 24;31(13):1867-1876
pubmed: 28590326
BMC Health Serv Res. 2021 May 17;21(1):463
pubmed: 34001123
Health Policy Plan. 2014 Jan;29(1):115-26
pubmed: 23325584
Lancet HIV. 2018 May;5(5):e241-e249
pubmed: 29650451
BMC Health Serv Res. 2022 Jan 14;22(1):69
pubmed: 35031037
PLoS One. 2022 Nov 22;17(11):e0277675
pubmed: 36413522
PLoS One. 2018 Jan 11;13(1):e0190659
pubmed: 29324811
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25321
pubmed: 31321918
J Acquir Immune Defic Syndr. 2018 May 1;78(1):16-19
pubmed: 29406431
Lancet HIV. 2021 May;8(5):e284-e293
pubmed: 33667411
J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):437-42
pubmed: 22046601
Trop Med Int Health. 2015 Dec;20(12):1634-5
pubmed: 26325025
JMIR Res Protoc. 2021 May 20;10(5):e27262
pubmed: 34014172
Med Care. 2012 Mar;50(3):217-26
pubmed: 22310560
Sex Transm Dis. 2016 Nov;43(11):690-695
pubmed: 27893598
Open AIDS J. 2016 Apr 08;10:34-48
pubmed: 27347270
BMC Infect Dis. 2020 Jun 22;20(1):432
pubmed: 32571230
J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):56-61
pubmed: 33044322
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25314
pubmed: 31321909
J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25307
pubmed: 31321889
PLOS Glob Public Health. 2023 Feb 10;3(2):e0001586
pubmed: 36962930
PLoS One. 2017 Oct 12;12(10):e0186316
pubmed: 29023510
Lancet HIV. 2017 Feb;4(2):e74-e82
pubmed: 27913227